Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Long QT Syndrome × Moxifloxacin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Solid Tumours 1 Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Long QT Syndrome 1 Hot Flashes 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Moxifloxacin 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03258515 2020-02-20

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

AstraZeneca

Phase 1 Completed

Long QT Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡